 Connection
Paul Bunn to Recombinant Proteins
This is a "connection" page, showing publications Paul Bunn has written about Recombinant Proteins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.254 |
|
|
|
-
Bunn PA, Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer. 1986 Apr 15; 57(8 Suppl):1689-95.
Score: 0.053
-
Bunn PA, Foon KA. Therapeutic options in advanced cutaneous T cell lymphomas: a role for interferon alfa-2a (Roferon-A). Semin Oncol. 1985 Dec; 12(4 Suppl 5):18-24.
Score: 0.051
-
Bunn PA, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ, Miller YE. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res. 1998 Nov; 4(11):2849-58.
Score: 0.031
-
Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct; 9(5):1089-107.
Score: 0.025
-
Roenigk HH, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PA, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):198S-205S.
Score: 0.018
-
Kaplan EH, Rosen ST, Norris DB, Roenigk HH, Saks SR, Bunn PA. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990 Feb 07; 82(3):208-12.
Score: 0.017
-
Bunn PA, Ihde DC, Foon KA. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas. Int J Cancer Suppl. 1987; 1:9-13.
Score: 0.014
-
Foon KA, Bunn PA. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia. Semin Oncol. 1986 Dec; 13(4 Suppl 5):35-9.
Score: 0.014
-
Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res. 1996 Feb 15; 56(4):831-9.
Score: 0.007
-
Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec; 13(12):2924-30.
Score: 0.006
-
Taylor CW, Chase EM, Whitehead RP, Rinehart JJ, Neidhart JA, Gonzalez R, Bunn PA, Hersh EM. A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer. J Immunother (1991). 1992 Apr; 11(3):176-83.
Score: 0.005
-
Kuzel TM, Gilyon K, Springer E, Variakojis D, Kaul K, Bunn PA, Evans L, Roenigk HH, Rosen ST. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990 Feb 07; 82(3):203-7.
Score: 0.004
-
Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, Franco S, Longo DL, Bunn PA, Ihde DC. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the S?zary syndrome. J Clin Oncol. 1990 Jan; 8(1):155-60.
Score: 0.004
-
Roth MS, Bunn PA, Foon KA. Interferon therapy for lymphoproliferative disorders. Cancer Treat Res. 1988; 38:231-52.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|